Payment overview · 2025
General Payments
$1,810.04
91 reported records · 27 companies
Healthcare provider profile · identity verified
Blake M Hodges, MD
Allopathic & Osteopathic Physicians|Family Medicine · ABBEVILLE, SC · NPI 1659710440
Verified facts
What the public records show
CMS Open Payments records show Blake M Hodges, MD received $1,810.04 in general payments during 2025 across 91 reported records.
ABBVIE INC. accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $258.78 | 14.3% | 15 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $254.93 | 14.1% | 10 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $157.10 | 8.7% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $148.95 | 8.2% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $103.47 | 5.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $100.85 | 5.6% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.41 | 5.5% | 6 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $95.48 | 5.3% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $85.26 | 4.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.14 | 3.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.42 | 3.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.70 | 2.9% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $45.78 | 2.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.39 | 1.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.28 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.68 | 1.6% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.09 | 1.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.32 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.50 | 1.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.80 | 1.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.34 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.15 | 0.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.82 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.28 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.24 | 0.8% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$13.86 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.02 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,810.04 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $196.03 | 11 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $157.10 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $148.95 | 9 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $141.25 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $113.68 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $110.79 | 7 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $103.47 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $100.85 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $99.41 | 6 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $95.48 | 5 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $85.26 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.42 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.42 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $51.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.96 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.96 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $45.78 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.03 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.39 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 401 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 90 |
| Lisinopril | Lisinopril | 241 | 81 |
| Gabapentin | Gabapentin | 231 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 95 |
| Omeprazole | Omeprazole | 207 | 75 |
| Furosemide | Furosemide | 196 | 65 |
| Famotidine | Famotidine | 182 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 48 |
| Losartan Potassium | Losartan Potassium | 171 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 41 |
| Lorazepam | Lorazepam | 131 | 26 |
| Metformin Hcl | Metformin Hcl | 125 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 36 |
| Glipizide | Glipizide | 120 | 37 |
| Ozempic | Semaglutide | 119 | 30 |
| Tramadol Hcl | Tramadol Hcl | 119 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 43 |
| Prednisone | Prednisone | 109 | 76 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 33 |
| Spironolactone | Spironolactone | 106 | 36 |
| Potassium Chloride | Potassium Chloride | 101 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 18 |
| Clonazepam | Clonazepam | 91 | 20 |
| Eliquis | Apixaban | 88 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 27 |
| Trazodone Hcl | Trazodone Hcl | 84 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 82 | 28 |
| Allopurinol | Allopurinol | 78 | 24 |
| Meloxicam | Meloxicam | 77 | 27 |
| Ibuprofen | Ibuprofen | 76 | 21 |
| Pregabalin | Pregabalin | 76 | 19 |
| Simvastatin | Simvastatin | 76 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 28 |
| Glipizide Er | Glipizide | 75 | 28 |
| Montelukast Sodium | Montelukast Sodium | 74 | 23 |
| Sertraline Hcl | Sertraline Hcl | 72 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 37 |
| Metformin Hcl Er | Metformin Hcl | 67 | 24 |
| Atenolol | Atenolol | 64 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 11 |
| Carvedilol | Carvedilol | 60 | 22 |
| Diazepam | Diazepam | 60 | 13 |
| Fluconazole | Fluconazole | 59 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 20 |
| Finasteride | Finasteride | 58 | 19 |
| Ezetimibe | Ezetimibe | 57 | 15 |
| Baclofen | Baclofen | 54 | 19 |
| Jardiance | Empagliflozin | 52 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 45 |
| Chlorthalidone | Chlorthalidone | 51 | 16 |
| Ketoconazole | Ketoconazole | 50 | 25 |
| Meclizine Hcl | Meclizine Hcl | 50 | 14 |
| Valsartan | Valsartan | 50 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Memantine Hcl | Memantine Hcl | 47 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Bupropion Xl | Bupropion Hcl | 43 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 38 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 42 | 14 |
| Mirtazapine | Mirtazapine | 42 | 14 |
| Clonidine Hcl | Clonidine Hcl | 41 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 11 |
| Celecoxib | Celecoxib | 38 | 17 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Amoxicillin | Amoxicillin | 36 | 33 |
| Levetiracetam | Levetiracetam | 36 | 12 |
| Nystatin | Nystatin | 35 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 16 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 12 |
| Fentanyl | Fentanyl | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | 13 |
| Acyclovir | Acyclovir | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 11 |
| Buspirone Hcl | Buspirone Hcl | 24 | 12 |
| Mupirocin | Mupirocin | 24 | 18 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | 11 |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 11 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Topiramate | Topiramate | 20 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Methimazole | Methimazole | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,810.04 · 91 records | ABBVIE INC. | BREZTRI, BRIUMVI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, Fintepla, Fluad, Flucelvax, GEMTESA, GIVLAARI, HYQVIA, Hizentra, JARDIANCE, KISUNLA, Korlym, LEQVIO, LINZESS, Leqembi, NUPLAZID, NURTEC ODT, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, Rystiggo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, VYVGART HYTRULO, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error